Sanofi Makes $27M Strategic Investment in Ventyx Biosciences
September 25, 2024
September 25, 2024
BOSTON, Massachusetts, Sept. 25 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray represented Sanofi in a $27 million strategic investment in Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on advancing oral therapies for a broad range of inflammatory diseases with significant unmet medical need.
Sanofi purchased 70,601 of the Company's Series A non-voting convertible preferred stock, each share of which is initially conve . . .
Ropes & Gray represented Sanofi in a $27 million strategic investment in Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on advancing oral therapies for a broad range of inflammatory diseases with significant unmet medical need.
Sanofi purchased 70,601 of the Company's Series A non-voting convertible preferred stock, each share of which is initially conve . . .